{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:49:06Z","timestamp":1783435746468,"version":"3.54.6"},"reference-count":48,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MA5799\/2-1"],"award-info":[{"award-number":["MA5799\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-018-0476-x","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T13:14:27Z","timestamp":1547126067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8389-8439","authenticated-orcid":false,"given":"Claudia","family":"Maletzki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Wiegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingy","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"476_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40425-018-0377-z","volume":"6","author":"PA Ascierto","year":"2018","unstructured":"Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, et al. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29\u201330 November, 2017, Naples, Italy). J Immunother cancer. England. 2018;6:69.","journal-title":"J Immunother cancer. England"},{"key":"476_CR2","doi-asserted-by":"publisher","unstructured":"Wrobel P, Ahmed S. Current status of immunotherapy in metastatic colorectal cancer. Int J Colorectal Dis. Germany. 2018. https:\/\/doi.org\/10.1007\/s00384-018-3202-8 .","DOI":"10.1007\/s00384-018-3202-8"},{"key":"476_CR3","doi-asserted-by":"publisher","unstructured":"Martin Lluesma S, Graciotti M, Chiang CL-L, Kandalaft LE. Does the immunocompetent status of Cancer patients have an impact on therapeutic DC vaccination strategies? Vaccines. Switzerland. 2018;6. https:\/\/doi.org\/10.3390\/vaccines6040079 .","DOI":"10.3390\/vaccines6040079"},{"key":"476_CR4","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-16-0903","volume":"22","author":"RM Chabanon","year":"2016","unstructured":"Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria JC, Postel-Vinay S. Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res. 2016;22:4309\u201321.","journal-title":"Clin Cancer Res"},{"key":"476_CR5","first-page":"1","volume":"117","author":"AP Cogdill","year":"2017","unstructured":"Cogdill AP, Andrews MC, Wargo JA. Hallmarks of response to immune checkpoint blockade. Br J Cancer Nature Publishing Group. 2017;117:1\u20137.","journal-title":"Br J Cancer Nature Publishing Group"},{"key":"476_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejca.2016.12.041","volume":"78","author":"E Giroux Leprieur","year":"2017","unstructured":"Giroux Leprieur E, Dumenil C, Julie C, Giraud V, Dumoulin J, Labrune S, et al. Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges. Eur J Cancer. Elsevier Ltd. 2017;78:16\u201323 Available from: https:\/\/doi.org\/10.1016\/j.ejca.2016.12.041 .","journal-title":"Eur J Cancer. Elsevier Ltd"},{"key":"476_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2017.01.001","volume":"74","author":"WCM Dempke","year":"2017","unstructured":"Dempke WCM, Fenchel K, Uciechowski P, Dale SP. Second- and third-generation drugs for immuno-oncology treatment-the more the better? Eur J Cancer. England. 2017;74:55\u201372.","journal-title":"Eur J Cancer. England"},{"key":"476_CR8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jcyt.2018.09.007","volume":"20","author":"D Galati","year":"2018","unstructured":"Galati D, Zanotta S. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. Cytotherapy. England. 2018;20:1309\u201323.","journal-title":"Cytotherapy. England"},{"key":"476_CR9","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3389\/fimmu.2018.02265","volume":"9","author":"WW Willigen van","year":"2018","unstructured":"van Willigen WW, Bloemendal M, Gerritsen WR, Schreibelt G, de Vries IJM, Bol KF. Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. Front Immunol. Switzerland. 2018;9:2265.","journal-title":"Front Immunol. Switzerland"},{"key":"476_CR10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12967-014-0245-7","volume":"12","author":"SA Fisher","year":"2014","unstructured":"Fisher SA, Cleaver A, Lakhiani DD, Khong A, Connor T, Wylie B, et al. Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. J Transl Med. England. 2014;12:245.","journal-title":"J Transl Med. England"},{"key":"476_CR11","doi-asserted-by":"publisher","unstructured":"Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, et al. Immune profiling of premalignant lesions in patients with lynch syndrome. JAMA Oncol. United States. 2018. https:\/\/doi.org\/10.1001\/jamaoncol.2018.1482 .","DOI":"10.1001\/jamaoncol.2018.1482"},{"key":"476_CR12","doi-asserted-by":"crossref","first-page":"112103","DOI":"10.18632\/oncotarget.22783","volume":"8","author":"K Yuza","year":"2017","unstructured":"Yuza K, Nagahashi M, Watanabe S, Takabe K, Wakai T. Hypermutation and microsatellite instability in gastrointestinal cancers. Oncotarget. 2017;8:112103\u201315.","journal-title":"Oncotarget"},{"key":"476_CR13","doi-asserted-by":"publisher","unstructured":"Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18:1009\u201321. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license; Available from: https:\/\/doi.org\/10.1016\/S1470-2045(17)30516-8 .","DOI":"10.1016\/S1470-2045(17)30516-8"},{"key":"476_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.01993","volume":"8","author":"JM Grenier","year":"2018","unstructured":"Grenier JM, Yeung ST, Khanna KM. Combination immunotherapy: taking cancer vaccines to the next level. Front Immunol. 2018;8:1\u20139.","journal-title":"Front Immunol"},{"key":"476_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.phrs.2016.05.007","volume":"110","author":"D Adah","year":"2016","unstructured":"Adah D, Hussain M, Qin L, Qin L, Zhang J, Chen X. Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics. Pharmacol Res. Elsevier Ltd. 2016;110:25\u201334 Available from: https:\/\/doi.org\/10.1016\/j.phrs.2016.05.007 .","journal-title":"Pharmacol Res. Elsevier Ltd"},{"key":"476_CR16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, et al. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Front Immunol. Switzerland. 2018;9:1310.","journal-title":"Front Immunol. Switzerland"},{"key":"476_CR17","doi-asserted-by":"publisher","unstructured":"Maletzki C, Gladbach YS, Hamed M, Fuellen G, Semmler M-L, Stenzel J, et al. Cellular vaccination of MLH1\u2212\/\u2212mice\u2013an immunotherapeutic proof of concept study. Oncoimmunology. 2018;7. https:\/\/doi.org\/10.1080\/2162402X.2017.1408748 .","DOI":"10.1080\/2162402X.2017.1408748"},{"key":"476_CR18","doi-asserted-by":"publisher","unstructured":"Maletzki C, Beyrich F, H\u00fchns M, Klar E, Linnebacher M. The mutational profile and infiltration pattern of murine MLH1\u2212\/\u2212tumors - concurrences, disparities and cell line establishment for functional analysis. Oncotarget. 2016;7. https:\/\/doi.org\/10.18632\/oncotarget.10677 .","DOI":"10.18632\/oncotarget.10677"},{"issue":"12","key":"476_CR19","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.18632\/oncotarget.2039","volume":"5","author":"C Maletzki","year":"2014","unstructured":"Maletzki C, Klier U, Marinkovic S, Klar E, Andr\u00e4 J, Linnebacher M. Host defense peptides for treatment of colorectal carcinoma-a comparative in vitro and in vivo analysis. Oncotarget. 2014;5(12):4467\u201379.","journal-title":"Oncotarget"},{"key":"476_CR20","first-page":"1301","volume-title":"Tumorigenesis in Mlh1 and Mlh1 \/ Apc1638N Mutant Mice Tumorigenesis in Mlh1 and Mlh1 \/ Apc1638N Mutant Mice 1","author":"W Edelmann","year":"1999","unstructured":"Edelmann W, Yang K, Kuraguchi M, Edelmann W, Yang K, Kuraguchi M, et al. Tumorigenesis in Mlh1 and Mlh1 \/ Apc1638N Mutant Mice Tumorigenesis in Mlh1 and Mlh1 \/ Apc1638N Mutant Mice 1; 1999. p. 1301\u20137."},{"key":"476_CR21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-319-67577-0_7","volume":"1036","author":"TS Johnson","year":"2017","unstructured":"Johnson TS, Mcgaha T, Munn DH. Chemo-immunotherapy: role of Indoleamine 2,3-dioxygenase in defining immunogenic versus Tolerogenic cell death in the tumor microenvironment. Adv Exp Med Biol United States. 2017;1036:91\u2013104.","journal-title":"Adv Exp Med Biol United States"},{"key":"476_CR22","first-page":"295","volume":"16","author":"LA Emens","year":"2010","unstructured":"Emens LA. Chemoimmunotherapy. Cancer J United States. 2010;16:295\u2013303.","journal-title":"Cancer J United States"},{"key":"476_CR23","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.molimm.2007.07.013","volume":"45","author":"ESK Rijkers","year":"2008","unstructured":"Rijkers ESK, de Ruiter T, Baridi A, Veninga H, Hoek RM, Meyaard L. The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol England. 2008;45:1126\u201335.","journal-title":"Mol Immunol England"},{"key":"476_CR24","doi-asserted-by":"publisher","unstructured":"Lang S, Bruderek K, Kaspar C, Hoing B, Kanaan O, Dominas N, et al. Clinical relevance and suppressive capacity of human myeloid-derived suppressor cell subsets. Clin Cancer Res. United States. 2018. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3726 .","DOI":"10.1158\/1078-0432.CCR-17-3726"},{"key":"476_CR25","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1021\/acs.molpharmaceut.7b01075","volume":"15","author":"D Yoyen-Ermis","year":"2018","unstructured":"Yoyen-Ermis D, Ozturk-Atar K, Kursunel MA, Aydin C, Ozkazanc D, Gurbuz MU, et al. Tumor-induced myeloid cells are reduced by gemcitabine-loaded PAMAM dendrimers decorated with anti-Flt1 antibody. Mol Pharm United States. 2018;15:1526\u201333.","journal-title":"Mol Pharm United States"},{"key":"476_CR26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/cas.12621","volume":"106","author":"S Mayanagi","year":"2015","unstructured":"Mayanagi S, Kitago M, Sakurai T, Matsuda T, Fujita T, Higuchi H, et al. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci England. 2015;106:397\u2013406.","journal-title":"Cancer Sci England"},{"key":"476_CR27","doi-asserted-by":"publisher","unstructured":"Maletzki C, Stier S, Gruenert U, Gock M, Ostwald C, Prall F, et al. Establishment, characterization and Chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas. PLoS One. 2012;7. https:\/\/doi.org\/10.1371\/journal.pone.0052485 .","DOI":"10.1371\/journal.pone.0052485"},{"key":"476_CR28","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ijc.28390","volume":"134","author":"L Pelosof","year":"2014","unstructured":"Pelosof L, Yerram SR, Ahuja N, Delmas A, Danilova L, Herman JG, et al. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer. Int J cancer United States. 2014;134:596\u2013605.","journal-title":"Int J cancer United States"},{"key":"476_CR29","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/0008-5472.CAN-13-3596","volume":"74","author":"ZC Ding","year":"2014","unstructured":"Ding ZC, Lu X, Yu M, Lemos H, Huang L, Chandler P, et al. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor cd4 t-cell responses through the PD-1-PD-L1 axis. Cancer Res. 2014;74:3441\u201353.","journal-title":"Cancer Res"},{"key":"476_CR30","doi-asserted-by":"crossref","unstructured":"Aric\u00f2 E, Sestili P, Carpinelli G, Canese R, Cecchetti S, Schiavoni G, et al. Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis. Oncotarget. 2016;7(37):59754\u201359765.","DOI":"10.18632\/oncotarget.10880"},{"key":"476_CR31","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet E, Larouche V, Campbell BB, Merico D, De Borja R, Aronson M, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016;34:2206\u201311.","journal-title":"J Clin Oncol"},{"key":"476_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ng.3202","volume":"47","author":"A Shlien","year":"2015","unstructured":"Shlien A, Campbell BB, De Borja R, Alexandrov LB, Merico D, Wedge D, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet. Nature Publishing Group. 2015;47:257\u201362 Available from: https:\/\/doi.org\/10.1038\/ng.3202 .","journal-title":"Nat Genet. Nature Publishing Group"},{"key":"476_CR33","doi-asserted-by":"crossref","unstructured":"Castellucci E, He T, Goldstein DY, Halmos B, Chuy J. DNA Polymerase \u025b Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity. Oncologist. 2017;22(5):497\u2013502.","DOI":"10.1634\/theoncologist.2017-0034"},{"key":"476_CR34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2468-1253(16)30014-0","volume":"1","author":"E Domingo","year":"2016","unstructured":"Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016;1:207\u201316.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"476_CR35","first-page":"CD009069","volume":"5","author":"M Arbyn","year":"2018","unstructured":"Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. England. 2018;5:CD009069.","journal-title":"Cochrane Database Syst Rev. England"},{"key":"476_CR36","first-page":"217","volume":"16","author":"EP Armstrong","year":"2010","unstructured":"Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm United States. 2010;16:217\u201330.","journal-title":"J Manag Care Pharm United States"},{"key":"476_CR37","doi-asserted-by":"crossref","unstructured":"Martin Lluesma S, Wolfer A, Harari A, Kandalaft LE. Cancer Vaccines in Ovarian Cancer: How Can We Improve? Biomedicines. 2016;4(2).","DOI":"10.3390\/biomedicines4020010"},{"key":"476_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.canlet.2017.06.018","volume":"403","author":"H Westdorp","year":"2017","unstructured":"Westdorp H, Kolders S, Hoogerbrugge N, de Vries IJM, Jongmans MCJ, Schreibelt G. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Lett. Elsevier Ltd. 2017;403:159\u201364 Available from: https:\/\/doi.org\/10.1016\/j.canlet.2017.06.018 .","journal-title":"Cancer Lett. Elsevier Ltd"},{"key":"476_CR39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.29724","volume":"138","author":"N Amayiri","year":"2016","unstructured":"Amayiri N, Tabori U, Campbell B, Bakry D, Aronson M, Durno C, et al. High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int J Cancer. 2016;138:380\u20135.","journal-title":"Int J Cancer"},{"key":"476_CR40","first-page":"31","volume":"2","author":"CA Thaiss","year":"2011","unstructured":"Thaiss CA, Semmling V, Franken L, Wagner H, Kurts C. Chemokines: a new dendritic cell signal for T cell activation. Front Immunol. Switzerland. 2011;2:31.","journal-title":"Front Immunol. Switzerland"},{"key":"476_CR41","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1158\/0008-5472.CAN-04-1261","volume":"64","author":"RB Mailliard","year":"2004","unstructured":"Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. United States. 2004;64:5934\u20137.","journal-title":"Cancer Res. United States"},{"key":"476_CR42","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1158\/1078-0432.CCR-17-2707","volume":"24","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, et al. Cytokines produced by dendritic cells administered Intratumorally correlate with clinical outcome in patients with diverse cancers. Clin Cancer Res United States. 2018;24:3845\u201356.","journal-title":"Clin Cancer Res United States"},{"key":"476_CR43","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1158\/1078-0432.CCR-16-3122","volume":"23","author":"JM Brown","year":"2017","unstructured":"Brown JM, Recht L, Strober S. The promise of targeting macrophages in Cancer therapy. Clin Cancer Res. United States. 2017;23:3241\u201350.","journal-title":"Clin Cancer Res. United States"},{"key":"476_CR44","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez FE, Gleisner A, Falc\u00f3n-Beas F, Osorio F, L\u00f3pez MN, Salazar-Onfray F. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother. 2014;10(11):3261\u20139.","DOI":"10.4161\/21645515.2014.982996"},{"key":"476_CR45","doi-asserted-by":"publisher","unstructured":"Dutcher GMA, Bilen MA. Therapeutic vaccines for genitourinary malignancies. Vaccines Switzerland. 2018;6. https:\/\/doi.org\/10.3390\/vaccines6030055 .","DOI":"10.3390\/vaccines6030055"},{"key":"476_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2016.1213933","volume":"5","author":"V Konduri","year":"2016","unstructured":"Konduri V, Li D, Halpert MM, Liang D, Liang Z, Chen Y, et al. Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D\/p53\u2212\/\u2212pancreatic ductal adenocarcinoma. Oncoimmunology. Taylor & Francis. 2016;5:1\u201310 Available from: https:\/\/doi.org\/10.1080\/2162402X.2016.1213933 .","journal-title":"Oncoimmunology. Taylor & Francis"},{"key":"476_CR47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/jmr.650","volume":"16","author":"P Gogolak","year":"2003","unstructured":"Gogolak P, Rethi B, Hajas G, Rajnavolgyi E. Targeting dendritic cells for priming cellular immune responses. J Mol Recognit. England. 2003;16:299\u2013317.","journal-title":"J Mol Recognit. England"},{"key":"476_CR48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"PG Coulie","year":"2014","unstructured":"Coulie PG, Van Den Eynde BJ, Van Der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. Nature Publishing Group. 2014;14:135\u201346 Available from: https:\/\/doi.org\/10.1038\/nrc3670 .","journal-title":"Nat Rev Cancer. Nature Publishing Group"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0476-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:47:16Z","timestamp":1601056036000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0476-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["476"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0476-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,10]]},"article-number":"8"}}